Matisse Capital Verastem, Inc. Transaction History

Matisse Capital

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 14, 2021	SELL	$1.9 - $2.82 $11,400 - $16,920	-6,000 Reduced 14.63%	35,000 $86,000
Q4 2020 Feb 12, 2021	SELL	$1.15 - $2.4 $5,750 - $12,000	-5,000 Reduced 10.87%	41,000 $87,000
Q3 2020 Nov 04, 2020	SELL	$1.11 - $1.68 $51,060 - $77,280	-46,000 Reduced 50.0%	46,000 $56,000
Q2 2020 Jul 28, 2020	SELL	$1.69 - $4.2 $50,700 - $126,000	-30,000 Reduced 24.59%	92,000 $158,000
Q1 2020 May 07, 2020	BUY	$1.26 - $3.38 $153,720 - $412,360	122,000 New	122,000 $322,000

297K

Ticker VSTM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 210,000,000
Market Cap $1.2B
Description
Verastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylat...

Get notified when there are updates to the investment portfolio of Matisse Capital, based on Form 13F filings with the SEC.

Stay updated on Matisse Capital with notifications on news.